Prestige Consumer Healthcare Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.1B-2.9% YoYTTM through 30 Jun 2026
Net Income $172M-19.8% YoYTTM through 30 Jun 2026
Free Cash Flow $235.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 54.7% |
| EBITDA Margin | 29.2% |
| Operating Margin | 28.4% |
| Net Margin | 15.6% |
Returns
10.1%ROE
5.4%ROA
4.5%ROIC
Balance Sheet Health
Debt / Equity0.53x
Current Ratio3.23x
Net Debt$936.1M
Cash & Equivalents$89.1M
Quality Metrics
Altman Z-Score1.60
Piotroski F-Score4 / 9
FCF Margin21.3%
Rule of 4036.6
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2026: $1.1B
Diluted EPS$3.57TTMFY2026: $3.91
Dividend
No dividend
Capital Allocation
Capex Intensity1.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| North American OTC Healthcare | $913.6M | -4.8% | View detailsExpected to benefit from the integration of the Breathe Right brand acquisition closed in June 2026. |
| International OTC Healthcare | $175.1M | -1.5% | View detailsExpected to expand significantly with the acquisition of LaCorium Health, which is expected to close in the second quarter of fiscal 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.